Zacks: Analysts Expect Evoke Pharma Inc (NASDAQ:EVOK) to Announce -$0.12 Earnings Per Share

Wall Street analysts expect Evoke Pharma Inc (NASDAQ:EVOK) to announce earnings of ($0.12) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Evoke Pharma’s earnings. Evoke Pharma reported earnings per share of ($0.14) during the same quarter last year, which would suggest a positive year-over-year growth rate of 14.3%. The company is expected to issue its next earnings results on Thursday, August 15th.

According to Zacks, analysts expect that Evoke Pharma will report full-year earnings of ($0.35) per share for the current financial year. For the next financial year, analysts expect that the company will post earnings of ($0.19) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03.

A number of equities analysts recently commented on EVOK shares. HC Wainwright reiterated a “hold” rating on shares of Evoke Pharma in a research note on Friday, August 9th. ValuEngine upgraded Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research upgraded Evoke Pharma from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research note on Tuesday.

Large investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new position in Evoke Pharma in the second quarter valued at approximately $37,000. Marshall Wace LLP acquired a new stake in Evoke Pharma in the 1st quarter worth about $139,000. Virtu Financial LLC acquired a new stake in Evoke Pharma in the 1st quarter worth about $118,000. Finally, BlackRock Inc. raised its stake in Evoke Pharma by 5.5% in the 4th quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock worth $207,000 after purchasing an additional 4,392 shares in the last quarter. Institutional investors and hedge funds own 7.40% of the company’s stock.

NASDAQ:EVOK traded up $0.02 during mid-day trading on Thursday, reaching $0.86. The stock had a trading volume of 135,076 shares, compared to its average volume of 712,145. The stock has a market cap of $19.31 million, a P/E ratio of -1.87 and a beta of 1.62. Evoke Pharma has a 1-year low of $0.50 and a 1-year high of $3.40. The business has a 50 day simple moving average of $0.89.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Recommended Story: What is meant by a buy rating?

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with's FREE daily email newsletter.